The clinical summary of thiazolidinediones in the treatment of T2DM.

doi:10.7504/nk2014090203

Abstract

Abstract:

Abstract：Thiazolidinediones are insulin sensitizers developed specifically for T2DM，which mainly act via decreasing insulin resistance of tissues，including adipocyte，liver，and muscular，and protecting pancreatic β cells to improving hyperglycemia and cholesterol.It is always a controversy whether or not thiazolidinediones have bigger clinical benefits than its risks.This article will attempt to illustrate the effect and safety based on science evidences of TZDs.

Key words: thiazolidinediones；peroxisome proliferator-activated receptor &gamma, ；T2DM

摘要：

噻唑烷二酮(TZDs)类药物属于胰岛素增敏剂用于治疗2型糖尿病，主要通过改善脂肪细胞、肝脏和肌肉组织胰岛素抵抗以及保护胰岛B细胞功能达到降低血糖和改善血脂的作用。此类药物的临床获益是否大于风险一直是争论的热点话题。文章通过阐述客观的循证学证据对该类药物的疗效与安全性进行全面介绍，从而帮助正确的使用该类药物提供依据。

关键词: 噻唑烷二酮类, 过氧化物酶体增殖剂激活受体&gamma, 2型糖尿病

CLC Number:

R587.1

CHEN Li-ming.. The clinical summary of thiazolidinediones in the treatment of T2DM.[J]. Acta Metallurgica Sinica, DOI: 10.7504/nk2014090203.

陈莉明. 噻唑烷二酮类药物治疗2型糖尿病的临床认识[J]. 中国实用内科杂志, DOI: 10.7504/nk2014090203.

References



[1］Rosen CJ.Revisiting the rosiglitazone story-lessons learned［J］.N Engl J Med，2010，363：803-806. 

[2］DeFronzo RA，Tripathy D，Schwenke DC，et al.Pioglitazone for diabetes prevention in impaired glucose tolerance［J］.N Engl J Med，2014，364(12)：1104-1115. 

[3］Gerstein HC，Yusuf S，Bosch J，et al.Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose：a randomised controlled trial［J］.Lancet，2006，368：1096-1105. 

[4］Xiang AH，Peters RK，Kjos SL，et al.Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes［J］.Diabetes，2006，55：517-522. 

[5］Knowler WC，Hamman RF，Edelstein SL，et al.Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program［J］.Diabetes，2005，54：1150-1156. 

[6］Aronoff S，Rosenblatt S，Braithwaite S，et al.Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes：a 6-month randomized placebo-controlled dose-response study.The Pioglitazone 001 Study Group［J］.Diabetes Care，2000，23(11)：1605-1611. 

[7］Rajagopalan R，Perez A，Ye Z，et al.Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus［J］.Drugs Aging，2004，21(4)：259-271. 

[8］Jain R，Osei K，Kupfer S，et al.Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus［J］.Pharmacotherapy，2006，26(10)：1388-1395. 

[9］Bolli G，Dotta F，Colin L，et al.Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin［J］.Diabetes Obes Metab，2009，11：589-595. 

[10］Charbonnel BH，Matthews DR，Schernthaner G，et al.A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus：a randomized，double-blind，parallel-group comparison trial［J］.Diabet Med，2005，22：399-405. 

[11］Tan MH，Baksi A，Krahulec B，et al.Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes［J］.Diabetes Care，2005，28：544-550. 

[12］Russell-Jones D，Cuddihy RM，Hanefeld M，et al.Efficacy and safety of exenatide once weekly versus metformin，pioglitazone，and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4)：a 26-week double-blind study［J］.Diabetes Care，2012，35：252-258. 

[13］Charbonnel B，Schernthaner G，Brunetti P，et al.Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes［J］.Diabetologia，2005，48：1093-1104. 

[14］Kahn SE，Haffner SM，Heise MA，et al.Glycemic durability of rosiglitazone，metformin，or glyburide monotherapy［J］.N Engl J Med，2006，355：2427-2443. 

[15］Tan MH，Johns D，Strand J，et al.Sustained effects of pioglitazone vs.glibenclamide on insulin sensitivity，glycaemic control，and lipid profiles in patients with Type 2 diabetes［J］.Diabet Med，2004，21：859-866. 

[16］Pfutzner A，Marx N，Lubben G，et al.Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control：results from the pioneer study［J］.J Am Coll Cardiol，2005，45：1925-1931. 

[17］Majali KA，Cooper MB，Staels B，et al.The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism，lipoprotein modification by lipases，and lipid transfer activities in type 2 diabetic patients［J］.Diabetologia，2006，49：527-537. 

[18］Goldberg RB，Kendall DM，Deeg MA，et al.A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia［J］.Diabetes Care，2005，28(7)：1547-1554. 

[19］Nissen SE，Wolski K.Rosiglitazone revisited：an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality［J］.Arch Intern Med，2010，170：1191-1201. 

[20］Lincoff AM，Wolski K，Nicholls SJ，et al.Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus：a meta-analysis of randomized trials［J］.JAMA，2007，298：1180-1188. 

[21］Mannucci E，Monami M，Lamanna C，et al.Pioglitazone and cardiovascular risk.A comprehensive meta-analysis of randomized clinical trials［J］.Diabetes Obes Metab，2008，10：1221-1238. 

[22］Selvin E，Bolen S，Yeh HC，et al.Cardiovascular outcomes in trials of oral diabetes medications：a systematic review［J］.Arch Intern Med，2008，168(19):2070-2080. 

[23］Mazzone T，Meyer PM，Feinstein SB，et al.Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes：a randomized trial［J］.JAMA，2006，296：2572-2581. 

[24］Nissen SE，Nicholls SJ，Wolski K，et al.Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes：the PERISCOPE randomized controlled trial［J］.JAMA，2008，299(13):1561-1573. 

[25］Dormandy JA，Charbonnel B，Eckland DJ，et al.Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)：a randomised controlled trial［J］.Lancet，2005，366：1279-1289. 

[26］Erdmann E，Dormandy JA，Charbonnel B，et al.The effect of pioglitazone on recurrent myocardial infarction in 2，445 patients with type 2 diabetes and previous myocardial infarction：results from the PROactive (PROactive 05) Study［J］.J Am Coll Cardiol，2007，49：1772-1780. 

[27］Wilcox R，Bousser MG，Betteridge DJ，et al.Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke：results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) ［J］.Stroke，2007，38：865-873. 

[28］Tzoulaki I，Molokhia M，Curcin V，et al.Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs：retrospective cohort study using UK general practice research database［J］.BMJ，2009，339：b4731. 

[29］Jacob AN，Salinas K，Adams-Huet B，et al.Weight gain in type 2 diabetes mellitus［J］.Diabetes Obes Metab，2007，9：386-393. 

[30］Ambrosius WT，Danis RP，Goff DC Jr，et al.Lack of association between thiazolidinediones and macular edema in type 2 diabetes：the ACCORD eye substudy［J］.Arch Ophthalmol，2010，128：312-318. 

[31］Home PD，Pocock SJ，Beck-Nielsen H，et al.Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD)：a multicentre，randomised，open-label trial［J］.Lancet，2009，373：2125-2135. 

[32］Graham DJ，Ouellet-Hellstrom R，MaCurdy TE，et al.Risk of acute myocardial infarction，stroke，heart failure，and death in elderly Medicare patients treated with rosiglitazone or pioglitazone［J］.JAMA，2010，304：411-418. 

[33］Dormandy J，Bhattacharya M，van Troostenburg de Bruyn AR.Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes：an overview of data from PROactive［J］.Drug Saf，2010，32：187-202. 

[34］Habib ZA，Havstad SL，Wells K，et al.Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus［J］.J Clin Endocrinol Metab，2010，95：592-600. 

[1]	. [J]. Acta Metallurgica Sinica, 2014, 34(12): 1212-1214.
[2]	. [J]. Acta Metallurgica Sinica, 2014, 34(12): 1219-1221.
[3]	YANG Wen-ying.. Clinical research and application of carbon glycosidase inhibitors. [J]. Acta Metallurgica Sinica, 2014, 34(10): 937-939.
[4]	ZHU Yan-hua，WENG Jian-ping.. The clinical experience of GLP-1 receptor agonist drugs. [J]. Acta Metallurgica Sinica, 2014, 34(10): 942-946.
[5]	LI Juan，TONG Nan-wei.. The clinical experience of glinides. [J]. Acta Metallurgica Sinica, 2014, 34(10): 959-961.
[6]	GU Guang-yu，ZHENG Shao-xiong.. SGLT2 inhibitors-new way for the treatment of type 2 diabetes. [J]. Acta Metallurgica Sinica, 2014, 34(10): 962-968.
[7]	ZHANG Li-na,GUO Li-xin.. The look at sulfonylurea compounds. [J]. Acta Metallurgica Sinica, 2014, 34(10): 969-973.
[8]	. [J]. Acta Metallurgica Sinica, 2014, 34(10): 974-983.
[9]	LI Yan-lai*，MA Yan-qing，SUN Ji-chao，SUN Wan-wan，WANG Tian-ge，XU Yu，XU Min，BI Yu-fang，LU Jie-li.. Elevated resting heart rate is associated with increased risk of diabetes in middle-aged and elderly population. [J]. Acta Metallurgica Sinica, 2014, 34(9): 900-903.
[10]	TONG Yu-zhen，TONG Nan-wei.. Interpretation of Chinese society of endocrinology expert consensus on type 2 diabetes prevention in Chinese adults [J]. Acta Metallurgica Sinica, 2014, 34(7): 671-677.
[11]	LIU Yuan-bo*，ZHOU Bo-rong，ZHANG Ying，O De-jin，XIE Yi-juan，MENG Dong-dong.. Comparison of Clopidogrel resistance and Cilostazol resistance in patients with type 2 diabetes. [J]. Acta Metallurgica Sinica, 2014, 34(7): 693-697.
[12]	. [J]. Acta Metallurgica Sinica, 2014, 34(7): 714-715.
[13]	. [J]. Acta Metallurgica Sinica, 2014, 34(6): 619-621.
[14]	. [J]. Acta Metallurgica Sinica, 2014, 34(5): 516-517.
[15]	LVQing-guo，TONG Nan-wei.. Interpretation of Chinese Society of Endocrinology consensus statement on hyperglycemia management target in adult inpatients in China. [J]. Acta Metallurgica Sinica, 2013, 33(12): 939-941.